We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Owlet's Data Flywheel Grows: Can AI Boost Lifetime Value?
Read MoreHide Full Article
Key Takeaways
OWLT is evolving into a data-driven pediatric health platform with over 650,000 active devices worldwide.
Over 85,000 paying subscribers and a 25% attach rate highlight traction in Owlet360 monetization.
AI-powered features, including tailored sleep coaching, are set to pilot in 2026 to drive lifetime value.
Owlet, Inc. (OWLT - Free Report) is steadily transforming from a connected baby monitor brand into a data-driven pediatric health platform, and its growing data flywheel is becoming central to that strategy. With more than 650,000 active devices globally and over 85,000 paying Owlet360 subscribers, the company is now generating a deep and expanding pool of longitudinal infant health and sleep data.
This growing dataset strengthens Owlet’s flywheel in two ways. First, higher device adoption feeds more biometric and behavioral data into the platform, improving insights and feature development. Second, richer insights increase the value of Owlet360, supporting higher subscription attach rates, stronger retention and longer customer lifetimes. Subscription attach rates have already moved past 25%, signaling early traction in monetizing this data advantage.
Artificial intelligence is the next lever. Owlet plans to layer AI-driven insights across its ecosystem, combining biometric data from Dream Sock with computer vision from the new Dream Sight camera. These capabilities are designed to deliver more personalized guidance around infant sleep, wellness and routines. Management has also outlined plans to pilot generative AI features in early 2026, including tailored sleep coaching based on a child’s unique patterns. If executed well, these features could meaningfully increase engagement and extend subscriptions beyond the infant stage.
The data flywheel also supports Owlet’s longer-term healthcare ambitions. Remote patient monitoring, hospital partnerships and telehealth initiatives benefit from validated data streams and clinical-grade insights, potentially opening higher-value channels than consumer hardware alone.
While execution risk remains, Owlet’s expanding dataset, improving profitability and disciplined cost structure position AI as a credible driver of higher lifetime value. As AI features roll out and subscriptions scale globally, the data flywheel may become one of Owlet’s most durable competitive assets.
Competitive Landscape: Masimo & Dexcom
In the race to turn biometric data into higher lifetime value, Masimo and Dexcom stand out as relevant comparables to Owlet’s expanding data flywheel. Masimo (MASI - Free Report) has built its franchise around clinically validated sensors and algorithms, using continuous physiological data to drive decision support across hospitals and home settings. Masimo’s long-standing emphasis on data accuracy, regulatory credibility and AI-assisted insights mirrors Owlet’s push to elevate infant monitoring beyond basic hardware into a trusted health platform. Masimo’s experience shows how proprietary datasets can reinforce switching costs and extend customer relationships over time.
Dexcom (DXCM - Free Report) offers another instructive parallel. Dexcom’s CGM ecosystem demonstrates how continuous data streams can be monetized through recurring revenue, software upgrades and analytics-driven insights. Dexcom has successfully used data and algorithms to improve outcomes, increase engagement and justify premium pricing. Together, Masimo and Dexcom highlight how data scale and AI integration can meaningfully expand lifetime value—an outcome that Owlet is increasingly targeting as its dataset and AI capabilities deepen.
The Zacks Consensus Estimate for OWLT’s 2026 loss has narrowed to 25 cents from 88 cents in the past 30 days. The company is expected to report 12 cents loss per share in 2025.
Image: Bigstock
Owlet's Data Flywheel Grows: Can AI Boost Lifetime Value?
Key Takeaways
Owlet, Inc. (OWLT - Free Report) is steadily transforming from a connected baby monitor brand into a data-driven pediatric health platform, and its growing data flywheel is becoming central to that strategy. With more than 650,000 active devices globally and over 85,000 paying Owlet360 subscribers, the company is now generating a deep and expanding pool of longitudinal infant health and sleep data.
This growing dataset strengthens Owlet’s flywheel in two ways. First, higher device adoption feeds more biometric and behavioral data into the platform, improving insights and feature development. Second, richer insights increase the value of Owlet360, supporting higher subscription attach rates, stronger retention and longer customer lifetimes. Subscription attach rates have already moved past 25%, signaling early traction in monetizing this data advantage.
Artificial intelligence is the next lever. Owlet plans to layer AI-driven insights across its ecosystem, combining biometric data from Dream Sock with computer vision from the new Dream Sight camera. These capabilities are designed to deliver more personalized guidance around infant sleep, wellness and routines. Management has also outlined plans to pilot generative AI features in early 2026, including tailored sleep coaching based on a child’s unique patterns. If executed well, these features could meaningfully increase engagement and extend subscriptions beyond the infant stage.
The data flywheel also supports Owlet’s longer-term healthcare ambitions. Remote patient monitoring, hospital partnerships and telehealth initiatives benefit from validated data streams and clinical-grade insights, potentially opening higher-value channels than consumer hardware alone.
While execution risk remains, Owlet’s expanding dataset, improving profitability and disciplined cost structure position AI as a credible driver of higher lifetime value. As AI features roll out and subscriptions scale globally, the data flywheel may become one of Owlet’s most durable competitive assets.
Competitive Landscape: Masimo & Dexcom
In the race to turn biometric data into higher lifetime value, Masimo and Dexcom stand out as relevant comparables to Owlet’s expanding data flywheel. Masimo (MASI - Free Report) has built its franchise around clinically validated sensors and algorithms, using continuous physiological data to drive decision support across hospitals and home settings. Masimo’s long-standing emphasis on data accuracy, regulatory credibility and AI-assisted insights mirrors Owlet’s push to elevate infant monitoring beyond basic hardware into a trusted health platform. Masimo’s experience shows how proprietary datasets can reinforce switching costs and extend customer relationships over time.
Dexcom (DXCM - Free Report) offers another instructive parallel. Dexcom’s CGM ecosystem demonstrates how continuous data streams can be monetized through recurring revenue, software upgrades and analytics-driven insights. Dexcom has successfully used data and algorithms to improve outcomes, increase engagement and justify premium pricing. Together, Masimo and Dexcom highlight how data scale and AI integration can meaningfully expand lifetime value—an outcome that Owlet is increasingly targeting as its dataset and AI capabilities deepen.
OWLT’s Price Performance, Valuation & Estimates
Shares of Owlet have gained 73.3% in the past six months, outperforming the Zacks Electronics - Miscellaneous Products industry’s 20.6% growth and the Zacks Computer and Technology sector’s 19.1% rise.
OWLT 6-Month Price Performance
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for OWLT’s 2026 loss has narrowed to 25 cents from 88 cents in the past 30 days. The company is expected to report 12 cents loss per share in 2025.
Image Source: Zacks Investment Research
OWLT currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.